Accelerating Bispecific Discovery with the Alloy Common Light Chain Platform
Webinar Overview
Discover the full potential of bispecific antibody therapeutics and how to accelerate their discovery during this presentation by Dr. Lucy Liu that reveals how Alloy’s technologies, services, and expertise is able to:
- Accelerate bispecific antibody discovery: Learn how the Alloy Common Light Chain (CLC) human, transgenic platform streamlines bispecific antibody discovery and development, minimizes challenges in engineering and manufacturability, and expedites the path to the clinic
- Overcome design challenges for complex targets: Discover how Alloys’ advanced platforms can discover potent antibodies against complex targets that were previously out of reach
- Maintain desired affinity across diverse designs: Full light chain (LC) diversity in formats that maintain desirable Fab and lgG structure
Webinar sample above. To access the full video content, fill out the form below.
About the Speaker:
Lucy Liu, PhD
Vice President, Head of Protein
Sciences & Bioanalytics
Alloy Therapeutics
Dr. Lucy Liu, Vice President and Head of Protein Sciences and Bioanalytics at Alloy Therapeutics, oversees the protein production and bioanalytics team to facilitate lead selection for partner discovery and engineering campaigns.
Previously, Dr. Liu led high throughput characterization at Compass Therapeutics and, prior to that, served as a project leader at Biogen.
Dr. Liu received her PhD in biochemistry from McGill University, after which she was a postdoctoral researcher at Dana-Farber Cancer Institute and worked as a postdoctoral scientist in EMO Serono’s in vitro antibody technologies group.
